# Mankind Pharma (NSE: MANKIND) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MANKIND · Pivot · prices to 22 Oct 2026

Mankind Pharma (NSE: MANKIND) closed at ₹2,236.60 on 22 Oct 2026, down 1.69% on the day. With a market capitalisation of ₹93,981 Cr, it ranks 114th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 48.4× trailing earnings, against a return on equity of 11.7% in FY26. Over the past year the share price has fallen 8.1%. Its 52-week range is ₹1,909.70 (23 Mar 2026) to ₹2,642.00 (29 Jul 2026); the last close is 15.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,031 Cr (+12.9% year on year) and net profit ₹570 Cr (+29.2%), on a consolidated basis. Promoters held 72.63% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,236.60 |
| Market cap | ₹93,981 Cr |
| P/E (trailing) | 48.4 |
| ROE | 11.7% (FY26) |
| ROCE | 14.3% (FY26) |
| Debt to equity | 0.38 |
| 52-week high | ₹2,642.00 (29 Jul 2026) |
| 52-week low | ₹1,909.70 (23 Mar 2026) |
| 1-year return | −8.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹4,031 Cr | +12.9% | ₹570 Cr | +29.2% | ₹13.76 |
| Q4 FY26 | ₹3,443 Cr | +11.8% | ₹556 Cr | +31.8% | ₹13.44 |
| Q3 FY26 | ₹3,567 Cr | +10.4% | ₹411 Cr | +7.8% | ₹9.90 |
| Q2 FY26 | ₹3,697 Cr | +20.2% | ₹518 Cr | −21.1% | ₹12.39 |
| Q1 FY26 | ₹3,570 Cr | +23.4% | ₹441 Cr | −18.1% | ₹10.62 |
| Q4 FY25 | ₹3,079 Cr | +26.1% | ₹422 Cr | −10.9% | ₹10.20 |
| Q3 FY25 | ₹3,230 Cr | +23.9% | ₹381 Cr | −16.3% | ₹9.45 |
| Q2 FY25 | ₹3,077 Cr | +13.6% | ₹656 Cr | +29.3% | ₹16.31 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹12,207 Cr | ₹1,999 Cr |
| FY24 | ₹10,335 Cr | ₹1,927 Cr |
| FY23 | ₹8,749 Cr | ₹1,297 Cr |
| FY22 | ₹7,782 Cr | ₹1,439 Cr |
| FY21 | ₹6,214 Cr | ₹1,281 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.63%
- Foreign institutions: 9.45%
- Domestic institutions: 15.39%
- Non-institutions: 2.53%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,569.50 | ₹1,09,341 Cr | 56 | 20.5% |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,010.10 | ₹1,08,185 Cr | 121.7 | 8.0% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,312.60 | ₹1,07,516 Cr | 27.3 | 11.3% |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,236.20 | ₹1,03,416 Cr | 25 | 11.1% |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,571.30 | ₹92,688 Cr | 26 | 9.2% |
| [Lupin](https://app.pivotnow.in/stock/LUPIN) | ₹1,929.60 | ₹87,880 Cr | 16.6 | 23.8% |

## Questions and answers

### What is the share price of Mankind Pharma today?

Mankind Pharma (NSE: MANKIND) last closed at ₹2,236.60 on 22 Oct 2026. Its 52-week high is ₹2,642.00 and its 52-week low is ₹1,909.70.

### What is the market cap of Mankind Pharma?

Mankind Pharma's market capitalisation is ₹93,981 Cr (₹93,981 Cr) at the 22 Oct 2026 close, ranking 114th among the NSE companies Pivot tracks.

### What is the P/E ratio of Mankind Pharma?

Mankind Pharma trades at a trailing P/E of 48.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 27.3.

### What is the ROE and ROCE of Mankind Pharma?

Return on equity was 11.7% in FY26 and return on capital employed was 14.3% in FY26 (consolidated figures).

### Is Mankind Pharma a debt-free company?

No. Mankind Pharma's debt-to-equity ratio was 0.38 in FY26, with total debt of ₹2,821 Cr.

### What were Mankind Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Mankind Pharma reported revenue of ₹4,031 Cr, +12.9% year on year, and net profit of ₹570 Cr, +29.2% year on year.

### How has Mankind Pharma stock performed over the last year?

Mankind Pharma's share price has fallen 8.1% over the past year, −11.7% over three months and −8.0% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Mankind Pharma?

As of 30 Jun 2026: promoters 72.63%, foreign institutions 9.45%, domestic institutions 15.39%, non-institutions 2.53%.

### Who are Mankind Pharma's competitors?

The listed Pharma & Healthcare companies closest to Mankind Pharma by market cap are Apollo Hospitals Enterprise, Laurus Labs, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma and Lupin.

### Is Mankind Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Mankind Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MANKIND against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.